Real-world retrospective analysis of patients who have received immune checkpoint inhibitors as a single agent in standard practice.
Latest Information Update: 16 Oct 2019
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Malignant melanoma; Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 16 Oct 2019 New trial record
- 04 Oct 2019 Results published in the European Journal of Cancer